Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.48 EUR | 0.00% | +3.50% | +8.03% |
Apr. 10 | Transgene: presents vaccine results at AACR | CF |
Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Sales 2023 | 7.9M 8.43M | Sales 2024 * | 39.8M 42.47M | Capitalization | 149M 159M |
---|---|---|---|---|---|
Net income 2023 | -22M -23.48M | Net income 2024 * | -13M -13.87M | EV / Sales 2023 | 17.6 x |
Net Debt 2023 | 1.63M 1.74M | Net Debt 2024 * | 16.4M 17.5M | EV / Sales 2024 * | 4.15 x |
P/E ratio 2023 |
-6.23
x | P/E ratio 2024 * |
-10.6
x | Employees | 143 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 34.45% |
Latest transcript on Transgene
1 week | +3.50% | ||
Current month | +29.82% | ||
1 month | +30.28% | ||
3 months | +9.31% | ||
6 months | +7.25% | ||
Current year | +8.03% |
Managers | Title | Age | Since |
---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 22-03-30 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 16-03-31 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 16-03-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 13-06-18 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 90-12-31 |
Director/Board Member | 63 | 04-12-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 1.48 | 0.00% | 25 843 |
24-04-17 | 1.48 | +2.07% | 44,937 |
24-04-16 | 1.45 | +0.14% | 57,250 |
24-04-15 | 1.448 | +3.43% | 122,604 |
24-04-12 | 1.4 | -2.10% | 70,976 |
Real-time Euronext Paris, April 18, 2024 at 07:32 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.03% | 158M | |
-3.39% | 102B | |
+2.61% | 96.84B | |
-0.82% | 21.48B | |
-18.14% | 20.82B | |
-7.26% | 18.6B | |
-40.70% | 16.81B | |
-26.89% | 13.78B | |
+1.12% | 13.4B | |
+22.25% | 11.06B |
- Stock Market
- Equities
- TNG Stock